Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors
(CARs) has shown promise, particularly for the treatment of hematological malignancies. To …

After initial infection, human cytomegalovirus remains in a persistent state with the host.
Immunity against the virus controls replication, although intermitent viral shedding can still …

Purpose Broadening trial eligibility to improve accrual and access and to better reflect
intended-to-treat populations has been recognized as a priority. Historically, patients with …

Abstract The Practice Guidelines Committee of the American Society for Transplantation and
Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to …

Immunocompromised individuals are at high risk for life-threatening diseases, especially
those caused by cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus …

Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality after
hematopoietic stem cell transplantation. Significant progress has been made in the …

Graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT)
is associated with considerable morbidity and mortality, particularly in patients who do not …

Adoptive transfer of CMV-specific T cells offers the potential for reconstitution of viral
immunity after allogeneic transplantation. However, the logistics of producing virus-specific T …

We analyzed the prognostic impact of donor and recipient cytomegalovirus (CMV)
serostatus in 16 628 de novo acute leukemia patients after allogeneic stem cell …

In the current era of effective prophylactic and preemptive therapy, cytomegalovirus (CMV) is
now a rare cause of early mortality after hematopoietic stem cell transplantation (HSCT) …